Clinical Trial Update: Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial assessed bevacizumab with or without the anti-endoglin monoclonal antibody TRC105 in patients with recurrent glioblastoma multiforme. The st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• TRC105 (carotuximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-05-23